Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Year range
1.
Article | IMSEAR | ID: sea-225915

ABSTRACT

This article reports a 74-year-old man came to the emergency department with complaint blood in urine, urinary tract symptom such as nocturia, frequency urgency, and cloudy urine.Physical examination showed suprapubic area was hard on palpation. The abdominal X-ray of the patient showed an opaque stone in the bladder. An ultrasound scan showed a multiple bladder stone with the longest stone 1.59 cm in size. Bilateral kidney cyst and the prostate was enlarged with volume �3.85 cc, IPP 2.29 cm. Entirestoneeliminationand eradicationrelatedBPH and urinary tract infections (UTIs) arethe principalgoalof theremedy. The patient was treated with Lithotripsy, antibiotics, alpha-blockers, antihypertension medications and showed clinical remission.

2.
Int J Pharm Pharm Sci ; 2020 Sep; 12(9): 36-40
Article | IMSEAR | ID: sea-206026

ABSTRACT

Objective: To assess Quality of life (QoL) and its associated factors in people living with HIV/AIDS (PLWHA) who taking highly active antiretroviral therapy (HAART) in Wangaya Hospital in Denpasar, Bali, Indonesia. Methods: A cross-sectional study was conducted during February 2019 to January 2020 at Wangaya Hospital in Denpasar, Bali, Indonesia. QoL was assessed using the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L), EQ-5D index value, and the EuroQol visual analogue scale (EQ-VAS). The data was analyzed using Statistical Package for Social Science (SPSS) software package version 26.0. Bivariate analysis was tested using the cross-tabulation Gamma, Kruskal-Wallis and post hoc Mann-Whitney test. P value<0.05 was considered as statistically significant. Results: A total of 584 PLWHA took HAART for at least 3 mo. The median index value and EQ-VAS were 1.0 (range-0.514–1.0) and 100.00 (range 30-100), respectively. Most patients had problems in ‘anxiety/depression’ and ‘pain/discomfort’ domains. Predictors of better QoL included men, married, good adherence, and treatment duration>24 mo (p<0.05). Predictor of poorer QoL included an advanced HIV clinical stage(p=0.001). Conclusion: The QoL scores of PLWHA receiving HAART in our study were high; hence the QoL of PLWHA was good. The good QoL can be taken as the goal for HIV treatment in order to have a successful HAART therapy.

3.
Int J Pharm Pharm Sci ; 2020 Sep; 12(9): 13-16
Article | IMSEAR | ID: sea-206022

ABSTRACT

Objective: Anemia is responsible for poor outcomes in HIV/AIDS patients. It’s related to disease progression, morbidity, and mortality. Antiretroviral therapy (ART) agent, zidovudine (ZDV) is also known to trigger anemia in the early initiation. However, studies found improved hemoglobin (Hb) levels of HIV/AIDS patients several months after ART routinely taken. This study aims to find the impact and correlation of ART on the hemoglobin level of HIV/AIDS patients. Methods: A retrospective cohort study was done at Merpati Clinic, Wangaya Hospital, Denpasar-Bali, Indonesia. Data were collected from medical records and laboratory results. A total sample of 64 HIV/AIDS patients with at least 6 mo on ART was included in this study. Results: Anemia was found in 34 (53.1%) of patients before ART initiation. After taking ART for 6 mo, we observed a significant improvement in patients’ hemoglobin levels, 48 (75%) shows increased hemoglobin levels. The paired t-test revealed a correlation between ART and Hb level (p<0.001). Fourteen (43.8%) patient taking ZDV shows no improvement, even declining of Hb level. Chi-square analysis performed with p = 0.001 to ZDV and lower or no improvement of hemoglobin level. Both results considered statistically significant (p-value less than 0.05) with a confidence interval (CI) of 95%. Relative risk (RR) of no improvement or decline in Hb level is 7 folds higher in the ZDV group than the non-ZDV group. Conclusion: This study concludes that ART affects hemoglobin levels in HIV/AIDS patients. Zidovudine regimen is more prone to lower or no increase of Hb.

4.
Int J Pharm Pharm Sci ; 2020 Jul; 12(7): 10-17
Article | IMSEAR | ID: sea-206117

ABSTRACT

Objective: To estimate the Pulmonary Tuberculosis (PTB) prevalence among the participants/People Living With HIV/AIDS (PLWHAs) and to verify the association between WHO clinical staging and other risk factors with PTB. Methods: A cross-sectional study was conducted to estimate the PTB prevalence. Probable associated risk factors in PLWHAs with and without PTB were compared. The association between WHO clinical staging and other risk factors with PTB was investigated using bivariate analysis. A p-value<0.05 was considered statistically significant. Results: This study was conducted from January 2018 to December 2019, recruited about 584 participants with presumptive PTB and 20.72% (121) confirmed with PTB. In the bivariate analysis; participants who are on human immunodeficiency virus (HIV) Stage 4 (WHO clinical staging) were significantly more likely to develop PTB (p=0.000). PTB was significantly higher among male than female (p=0.000), higher among the older (p=0.030). PTB was significantly more frequent among participants with lower cluster differentiation 4 (CD4) cell counts (p=0.042). A contact history with a Tuberculosis (TB) patient was an important risk factor (p=0.000). PTB was significantly associated with smoking history (p=0.000). Conclusion: A high PTB prevalence was observed. There was a significantly association between the severity of WHO clinical staging, sex, age, lower CD4 cell count, a contact history with a tuberculosis (TB) patient and smoking history with PTB among PLWHAs.

5.
Int J Pharm Pharm Sci ; 2020 Jun; 12(6): 59-67
Article | IMSEAR | ID: sea-206110

ABSTRACT

Objective: Infections contributed to higher morbidity and mortality in people living with HIV/AIDS (PLWHA) in both developed and developing countries. This study aimed to describe the spectrum of opportunistic infections (OIs) and associated factors among PLWHA on highly active antiretroviral therapy (HAART) at Merpati Clinic, Wangaya Regional General Hospital in Denpasar, Bali. Methods: This was a retrospective study. All of PLWHA, who still receiving HAART at Merpati Clinic from January 2018 to January 2020, who met inclusion and exclusion criteria, were included as subjects in this study. All data were collected through a review of the complete medical record of patients. Results: The prevalence of OIs in this study was 43.4%. Most PLWHA who experienced OIs were male (68.8%), age ≤40 y old with a median of age 36 y old, educational status senior high school (57.7%), married (62.1%), employed (89.7%), CD4 cell count ≥ 200 cells/µl (67.6%) and transmission route of HIV non-Intravenous (IV) drug user (99.2%). Sex, age, marital status, and CD4 cell count were significantly associated with OIs, p=0.000, p=0.005, p=0.005, and p=0.000, respectively. Conclusion: The commonest OI in this study was pulmonary tuberculosis. The presence of OIs was associated with sex, age of HIV diagnosis, marital status, and CD4 cell count. With the knowledge of OIs spectrum, clinicians are expected to be able to prevent, diagnose and treat OIs promptly to decrease the morbidity and mortality caused by OIs efficiently.

6.
Int J Pharm Pharm Sci ; 2020 May; 12(5): 80-84
Article | IMSEAR | ID: sea-206098

ABSTRACT

Pneumocystis Carinii Pneumonia (PCP) and Pulmonary Tuberculosis (PTB) are the most frequent Opportunistic Infection (OI) in People living with HIV/AIDS (PLWHA), especially whose CD4 counts<200 cells/mL. There is no pathognomonic sign and symptom of pneumocystis, radiographic imaging (chest radiograph) and blood examination. An intractable microorganism cannot be isolated or sustained in culture. The diagnosis of PCP is complicated, based on the presumptive diagnosis. PCP should be treated optimally as soon as possible in order not to be fatal. We report a complicated case of a female 26 y-old, diagnosed with HIV infection on Highly Active Anti Retro Viral Therapy (HAART), PTB on Anti Tuberculosis Drugs (ATD) concurrent with PCP. She also has a history of various Drug Hypersensitivity Reactions (DHR) include Rifampycin, Ciprofloxacin and Cotrimoxazole. DHR is unpredictable, and Clindamycin and Primaquin are the recommended alternative drugs for PCP, the strategic therapy is by Desensitization Protocols.

SELECTION OF CITATIONS
SEARCH DETAIL